Kamada KMDA
NASDAQ KMDA
$8.20 -0.09 (-1.09%)
As of: Sep 9, 2026 · 3:37 PM EDT

Kamada (KMDA) Net Income towards Common Stockholders (2012 - 2026)

Kamada's (KMDA) quarterly Net Income towards Common Stockholders came in at $11.1 million in Q2 2026, up 169.15% on a YoY basis from $4.1 million in Q2 2025, and up 67.16% quarter-over-quarter from $6.6 million in Q1 2026.

Analysis

Kamada (KMDA) Net Income towards Common Stockholders (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Net Income towards Common Stockholders for 15 consecutive years, with $11.1 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Net Income towards Common Stockholders rose 169.15% year-over-year to $11.1 million; the trailing twelve-month figure through Jun 2026 stood at $31.1 million (up 67.86% YoY), and the FY2025 full-year result was $26.7 million, up 119.04% from the prior year.
  • Net Income towards Common Stockholders rose to $11.1 million in Q2 2026 per KMDA's latest filing, from $6.6 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $11.1 million in Q2 2026 and bottomed at -$3.9 million in Q2 2022.
  • Historically, Net Income towards Common Stockholders has averaged $3.5 million across 5 years, with a median of $3.6 million in 2023.
  • The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders tumbled 518.46% in 2022, then jumped 565.91% in 2023.
  • Over 5 years, Net Income towards Common Stockholders stood at $2.9 million in 2022, then surged by 69.5% to $5.0 million in 2023, then tumbled by 77.76% to $1.1 million in 2024, then jumped by 432.07% to $5.9 million in 2025, then jumped by 88.22% to $11.1 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $11.1 million, $6.6 million, and $5.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Amgen 211.77 Bn 197.79 Bn 7.24 Bn 2.38 Bn
2 Gilead Sciences 181.13 Bn 177.95 Bn 6.22 Bn -10.50 Bn
3 Vertex Pharmaceuticals 132.24 Bn 124.39 Bn 2.84 Bn 1.10 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.89 Bn 3.93 Bn 1.30 Bn
5 Argenx Se 61.56 Bn 56.38 Bn 1.37 Bn 472.00 Mn
6 Moderna 54.38 Bn 49.24 Bn 52.00 Mn -782.00 Mn
7 Alnylam Pharmaceuticals 34.44 Bn 31.13 Bn 992.69 Mn 164.49 Mn
8 Biogen 31.17 Bn 29.89 Bn 1.96 Bn 97.50 Mn
9 Roivant Sciences 30.12 Bn 30.12 Bn 1.16 Mn -290.61 Mn
10 Kamada 473.28 Mn 403.14 Mn 22.47 Mn 11.12 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 11.12 Mn
Mar 31, 2026 6.65 Mn
Dec 31, 2025 5.91 Mn
Sep 30, 2025 7.44 Mn
Jun 30, 2025 4.13 Mn
Mar 31, 2025 9.26 Mn
Dec 31, 2024 1.11 Mn
Sep 30, 2024 4.03 Mn
Jun 30, 2024 4.55 Mn
Mar 31, 2024 2.51 Mn
Dec 31, 2023 4.99 Mn
Sep 30, 2023 3.22 Mn
Jun 30, 2023 1.81 Mn
Mar 31, 2023 -1.81 Mn
Dec 31, 2022 2.94 Mn
Sep 30, 2022 484,000.00
Jun 30, 2022 -3.92 Mn
Mar 31, 2022 -1.83 Mn
Dec 31, 2021 -4.66 Mn
Sep 30, 2021 -845,000.00